FREDERICK, Md., April 9, 2008 /PRNewswire-FirstCall/ -- BioElectronics
Corporation, (Pink Sheets: BIEL), announced today that the company will
start airing a new commercial for its ActiPatch (TM) technology on
Bloomberg Television, April 14, 2008. The company has initiated an
advertising contract that calls for the informational commercial to run for
the next two weeks, and will reach millions of viewers daily. CEO Andrew
Whelan comments, "This is a new initiative for BioElectronics Corporation
and we are excited that this commercial will inform consumers, physicians,
and distributors about our ActiPatch(TM) products. This national
advertisement should help us reach a new level in both product and brand
awareness."
The new bio-electronic super-bandage has produced significant rapid
healing results in trials and has already received regulatory clearance by
the FDA for the treatment of edema following blepharoplasty.
"ActiPatch (TM)" is very thin, easily applied and comfortable to wear
on an injured area. The patch effectively minimizes pain and swelling.
Physicians are so impressed with the power of the patch that they are
providing it to their patients for uses beyond plastic surgery recovery.
Trials are ongoing in multiple areas.
The new ActiPatch(TM) retail product line targets five common
conditions that affect hundreds of millions of people throughout the world:
1) Back pain, 2) Foot and ankle pain, including ankle sprains and plantar
fasciitis, 3) Knee pain, 4) Arm and wrist pain, including carpal tunnel and
tennis elbow. BioElectronics has planned an aggressive retail introduction
of these products for locations outside of the United States where
regulatory clearance has been received. Distribution is expected in Canada,
Italy, Netherlands, Australia, Mexico, United Kingdom, the Middle East, and
other countries over the next few months.
About BioElectronics
BioElectronics Corporation is the maker of the ActiPatch(TM).
ActiPatch(TM) is a drug free anti-inflammatory patch with an embedded
battery operated microchip that delivers weeks of continuous pulsed therapy
for less than a dollar a day. The unique ActiPatch(TM) delivery system,
using patented technology, provides a cost-effective patient friendly
method to reduce soft tissue pain and swelling.
For more information visit: http://www.bioelectronicscorp.com
Safe Harbor Statement
This news release contains forward-looking statements related to future
growth and earnings opportunities. Such statements are based upon certain
assumptions and assessments made by management of both companies In light
of current conditions, expected future developments and other factors it
believes to be appropriate. Actual results may differ as a result of
factors over which the company has no control.
See Also
- New Therapy by Merck is Positioned to Earn Gold-Standard Status by 2011 in the Treatment of Chemotherapy-Induced Nausea and Vomiting
- Town Health and Ping An Insurance (Group) Company of China, Ltd. Join Forces to Develop and Manage Clinic Chain in Pearl River Delta Area
- Sen. Robert Byrd Receives AOA Health Care Leadership Award
- Sen. Max Baucus Receives AOA Health Care Leadership Award
Via: Healthcare
0 коментарі:
Post a Comment